

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
10 January 2002 (10.01.2002)

PCT

(10) International Publication Number
WO 02/02609 A1

(51) International Patent Classification⁷: **C07K 14/435**,
14/47, A61K 35/12, A61P 35/00

(21) International Application Number: PCT/SE01/01387

(22) International Filing Date: 19 June 2001 (19.06.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0002551-0 6 July 2000 (06.07.2000) SE

(71) Applicant (for all designated States except US): **BIOVIT-
RUM AB** [SE/SE]; S-112 76 Stockholm (SE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **BERKENSTAM,**
Anders [SE/SE]; Langholmsgatan 11, S-117 33 Stockholm
(SE). **BERTILSSON, Göran** [SE/SE]; Kronobergsgatan
5, S-112 33 Stockholm (SE). **POELLINGER, Lorenz**
[SE/SE]; St. Eriksgatan 28, S-112 39 Stockholm (SE).

(74) Agent: **HÖGLUND, Lars**; Biovitrum AB, S-112 76
Stockholm (SE).

(81) Designated States (*national*): AE, AL, AM, AT, AU, AZ,
BA, BB, BG, BR, BY, CA, CH, CN, CO, CR, CU, CZ, DE,
DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID,
IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,
LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL,
PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ,
UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments
- with sequence listing part of description published sepa-
rately in electronic form and available upon request from
the International Bureau

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: INHIBITORY PAS DOMAIN PROTEIN (IPAS) AND SCREENING METHODS RELATED TO ANGIOGENESIS
AND TUMOR PROGRESSION

(57) Abstract: The present invention relates a mammalian polypeptide designated Inhibitory PAS Domain Protein (IPAS) which
polypeptide is useful for the inhibition of angiogenesis and/or tumor progression. The invention also relates to screening methods for
compounds potentially useful as medicaments for the treatment of medical conditions related to angiogenesis or tumor progression.

WO 02/02609 A1

Inhibitory PAS domain protein (IPAS) and screening methods related to angiogenesis and tumor progression

TECHNICAL FIELD

5 The present invention relates a mammalian polypeptide designated Inhibitory PAS Domain Protein (IPAS) which polypeptide is useful for the inhibition of angiogenesis and/or tumor progression. The invention also relates to screening methods for compounds potentially useful as medicaments for the treatment of medical conditions related to angiogenesis or tumor progression.

BACKGROUND ART

15 Oxygen plays a critical biological role as the terminal electron acceptor in the mitochondria of vertebrate cells. During evolution, these cells have developed ways to sense alterations in oxygen levels and, during this process, acquired the ability to conditionally modulate the expression of genes involved in adaptive physiological responses to hypoxia including angiogenesis, erythropoiesis, and glycolysis. These genes include vascular endothelial growth factor, erythropoietin, several glycolytic enzymes and inducible nitric oxide
20 synthase, and have all been shown to contain hypoxia responsive elements (HREs) (for reviews, see Guillemin and Krasnow (1997) Cell 89, 9-12; Wenger and Gassmann (1997) Biol. Chem. 378, 609-616). Under hypoxic conditions these response elements are recognized by a heterodimeric complex consisting of the hypoxia inducible factor-1 α (HIF-1 α) and Arnt (Wang et al. (1995) Proc. Natl. Acad. Sci. USA 92, 5510-5514; Gradin et al.
25 (1996) Mol. Cell. Biol. 16, 5221-5231). Both these transcription factors belong to the rapidly growing family of basic-helix-loop-helix (bHLH)-PAS (Per, Arnt, Sim) proteins.

A family of helix-loop-helix proteins designated Id¹⁸ has been identified as antagonists of bHLH transcriptional regulators. bHLH proteins typically bind regulatory sequences in a
30 heterodimeric configuration and function to activate differentiation-linked gene expression. The heterodimer usually comprises a class A bHLH protein together with a class B bHLH

- 2 -

protein. In the presence of excess Id protein, the class A bHLH partner is typically titrated out through heterodimerization with Id protein.

Dysregulation or overfunction of HIF-1 α might cause a variety of pathological conditions including tumor progression^{15 16 7} and inflammatory angiogenesis¹⁷. Consequently, there is a need for identification of compounds acting as negative regulators of HIF-1 α , said compounds being potentially useful against medical conditions related to angiogenesis and tumor progression.

DESCRIPTION OF THE DRAWINGS

Fig. 1: Mouse IPAS sequence and expression

(a)

Deduced amino acid sequence of mouse IPAS. Domains of basic helix-loop-helix and PAS A and B are shown.

(b)

Schematic representation of structural features of IPAS and the hypoxia-inducible factors. The percent identities of each protein with IPAS within the bHLH and PAS motifs are shown. bHLH, basic helix-loop-helix; PAS, Per/Arnt/Sim; N- or C-TAD, N- or C-terminal transactivation domain.

(c)

Northern blot analysis of IPAS expression in adult mouse tissues. Poly(A)⁺ RNA(4.5 μ g) from various adult mouse tissues were hybridized with ³²P-labeled IPAS cDNA probe. The positions of RNA markers are shown on the right in kb.

(d)-(o)

In situ hybridization analysis. Sections of cornea (d-g), retina (h-k), and cerebellum (l-o) of adult mouse were hybridized with antisense RNA probes of mIPAS (d, e, h, i, l, and m) or mHIF-1 α (f, g, j, k, n, and o). Light- (d, f, h, j, l, and n) and dark-field (e, g, i, k, m, and o) views are shown. C, cornea; Ep, epithelium; S, substantia propria; LE, lens epithelium; GC, granular cell layer; INL, inner nuclear layer; R&C, rods and cones, G, granular layer; P, Purkinje cells; M, molecular layer.

Fig. 2: IPAS is a dominant negative regulator of hypoxia-inducible factors

(a)

IPAS does not transactivate HRE-driven reporter gene. Increasing amounts of IPAS expression vector (CMV IPAS) were cotransfected with HRE-luciferase reporter gene into HeLa cells. The cells were cultured under either normoxic (21% O₂) or hypoxic (1% O₂) conditions for 24 h and the cellular luciferase expression was determined.

(b), (c)

IPAS inhibits hypoxia-inducible factors-mediated gene expression. IPAS expression vector, HRE-luciferase reporter, and HIF-1 α (b) or HLF (c) expression vector (CMV HIF-1 α or CMV HLF, respectively) were introduced into HeLa cells. After 24 h-incubation in normoxic (21% O₂) or hypoxic (1% O₂) condition, luciferase activity was measured. Results were expressed as fold induction compared with the luciferase activity in the cells transfected with reporter gene alone. Means \pm SD were shown.

(d)

IPAS does not affect on HIF-1 α and HLF protein levels. HeLa cells were transfected with FLAG-tagged IPAS expression plasmid (1.0 μ g/21.5 cm² dish) and exposed to hypoxia for 6 h. Whole cell extracts (50 μ g) were prepared and subject to immunoblot analysis using antibodies against HIF-1 α (Novus), HLF (Novus), and FLAG epitope (Sigma) essentially as previously described ⁶.

Fig. 3: IPAS specifically attenuates hypoxia-inducible mRNAs expression

(a)

Hypoxia-inducible gene expression is impaired in IPAS overexpressing cells. Wild
5 type(Hepa1c1c7) or IPAS-stably transfected (Hepa IPAS) mouse hepatoma cell lines were
cultured in either normoxic (N) or hypoxic (H) conditions for 24h. Poly(A)⁺ RNA from the
cells were separated and hybridized with radiolabeled mouse IPAS, PGK1, VEGF, and β -
actin cDNA probe as indicated.

10 (b)

Inhibition of hypoxia-inducible gene expression by IPAS at transcriptional level. HRE-
luciferase reporter was transfected with or without HIF-1 α expression vector into
Hepa1c1c7 or Hepa IPAS cells. The cells were cultured under conditions of either 21 % or
1 % O₂ concentration and subject to luciferase assay. Luciferase content of the Hepa1c1c7
15 cells transfected with the reporter gene alone was served as a control and results were
shown as fold induction compared with the control.

(c)

IPAS inhibits the binding of HIF-1 α /Arnt complex to HRE. Nuclear extracts from
20 normoxic or hypoxic Hepa1c1c7 and Hepa IPAS cells were analyzed by EMSA using ³²P-
labeled HRE oligonucleotide probe. The asterisks shows position of constitutive HRE-
binding activity in the nuclear extracts and arrow shows the position of hypoxia-induced
HIF-1 α /Arnt-DNA complex ¹². Competition assay by unlabeled HRE (S) or unrelated
sequence(NS) and supershift formation by anti HIF-1 α antibody and anti-Arnt antibody
25 were shown.

(d)

IPAS does not affect on dioxin-inducible gene expression. Hepa1c1c7 and Hepa IPAS cells
were treated with or without TCDD (10 nM) for 24 h and poly(A)⁺ RNA from the cells was
30 hybridized with ³²P-labeled mouse CYP1A1, IPAS, and β -actin cDNA probe.

(e)

IPAS has no effect on TCDD-mediated XRE-reporter gene expression. Hepalcl7 and Hepa IPAS cells were transfected with XRE-reporter plasmid and after incubation with or without TCDD for 24h luciferase activity was monitored. Results were expressed as fold induction of luciferase activity compared to the ligand free control of Hepalcl7 cells. Means \pm SD were shown.

Fig. 4: IPAS targets HIF-1 α to form a nonfunctional complex

(a)

IPAS physically interacts with HIF-1 α . In vitro-translated GST-IPAS or GST was mixed with ³⁵S-labeled, in vitro translated Arnt or HIF-1 α and immunoprecipitation with anti-GST antibody was carried out. The precipitant was separated by SDS-PAGE followed by autoradiography. For the loading control, 10% of input Arnt and HIF-1 α were shown.

(b)

The N-terminal structure of HIF-1 α is essential for the heterodimerization with IPAS. ³⁵S-labeled, in vitro translated IPAS was incubated with GAL4-fusion of various fragments of HIF-1 α and subject to the immunoprecipitation with either anti GAL4 antibody or preimmune control serum. Precipitated fraction was analyzed by SDS PAGE and results were obtained by autoradiography. Ten percent of input IPAS was shown as a control.

(c), (d)

In vivo interaction between IPAS and HIF-1 α . COS7 cells were transfected with various amounts of expression vectors for GAL4- HIF-1 α /1-330 and VP16-IPAS (c) or GAL4-IPAS and VP16-Arnt (d) as indicated together with GAL4-driven reporter gene. After 24h-incubation, cellular luciferase activity was determined. Results were expressed as fold induction compared with the luciferase contents of the cells transfected with reporter gene alone.

(e)

IPAS/HIF-1 α heterodimer fails to bind to HRE. Various combinations of in vitro translated IPAS, HIF-1 α , and Arnt, or unprogrammed reticulocyte lysate as indicated were mixed with ³²P-labeled HRE oligonucleotide probe, and the protein-DNA complex formation was monitored by EMSA. Results were visualized by autoradiography.

Fig. 5: Involvement of IPAS in silencing the production of angiogenic growth factor in cornea epithelium cells

Primary culture of mouse cornea epithelium cells were transfected with either antisense IPAS expression plasmid or empty vector (vector) and incubated under normoxic (N, 21% O₂) or hypoxic (H, 1% O₂) conditions for 24 h. Total RNAs from the cells were extracted and Northern blot analysis using radiolabeled mouse VEGF cDNA probe was performed. Total RNAs from normoxic and hypoxic Hepa1c1c7 cells were supplied as a reference for VEGF induction. As a loading control, 18S RNA levels are shown.

DISCLOSURE OF THE INVENTION

The present invention provides a model wherein activated HIF-1 α encounters a negative regulation by a small protein factor such as IPAS, to form a nonfunctional heterodimeric complex. This mode of regulation of HIF-1 α might contribute to a fine-tuning of hypoxia signaling *in situ* as evidenced by profound negative effect of IPAS in corneal VEGF production. On the other hand, ectopic expression of IPAS potentially repressed hypoxia-inducible VEGF expression, and the negative effect of IPAS was selective to hypoxia signaling so far tested. Therefore, it is postulated that IPAS is useful as a target in therapeutic drug design for various angiogenic diseases, such as ischemic cardiovascular lesions, stroke, and diabetic microvascular diseases.

Consequently, in a first aspect this invention provides an isolated nucleic acid molecule selected from:

- 7 -

- (a) nucleic acid molecules comprising a nucleotide sequence set forth as SEQ ID NO: 2;
- (b) nucleic acid molecules comprising a nucleotide sequence capable of hybridizing, under stringent hybridization conditions, to a nucleotide sequence complementary the polypeptide coding region of a nucleic acid molecule as defined in (a) and which codes for a
- 5 biologically active mammalian IPAS polypeptide or a functionally equivalent modified form thereof; and
- (c) nucleic acid molecules comprising a nucleic acid sequence which is degenerate as a result of the genetic code to a nucleotide sequence as defined in (a) or (b) and which codes for a biologically active mammalian IPAS polypeptide or a functionally equivalent
- 10 modified form thereof.

The nucleic acid molecules according to the present invention includes cDNA, chemically synthesized DNA, DNA isolated by PCR, genomic DNA, and combinations thereof. Genomic DNA may be obtained by screening a genomic library with the IPAS cDNA

15 described herein, using methods that are well known in the art. RNA transcribed from DNA is also encompassed by the present invention.

The term "stringent hybridization conditions" is known in the art from standard protocols (e.g. Ausubel et al., *supra*) and could be understood as e.g. hybridization to filter-bound

20 DNA in 0.5 M NaHPO₄, 7% sodium dodecyl sulfate (SDS), 1 mM EDTA at +65°C, and washing in 0.1xSSC / 0.1% SDS at +68°C.

In a preferred form of the invention, the said nucleic acid molecule has a nucleotide sequence identical with SEQ ID NO: 2 of the Sequence Listing. However, the nucleic acid

25 molecule according to the invention is not to be limited strictly to the sequence shown as SEQ ID NO: 2. Rather the invention encompasses nucleic acid molecules carrying modifications like substitutions, small deletions, insertions or inversions, which nevertheless encode proteins having substantially the biochemical activity of the IPAS polypeptide according to the invention. Included in the invention are consequently nucleic

30 acid molecules, the nucleotide sequence of which is at least 90% homologous, preferably at

least 95% homologous, with the nucleotide sequence shown as SEQ ID NO: 2 in the Sequence Listing.

Included in the invention is also a nucleic acid molecule which nucleotide sequence is degenerate, because of the genetic code, to the nucleotide sequence shown as SEQ ID NO: 2. A sequential grouping of three nucleotides, a "codon", codes for one amino acid. Since there are 64 possible codons, but only 20 natural amino acids, most amino acids are coded for by more than one codon. This natural "degeneracy", or "redundancy", of the genetic code is well known in the art. It will thus be appreciated that the nucleotide sequence shown in the Sequence Listing is only an example within a large but definite group of sequences which will encode the IPAS polypeptide.

In a further aspect, this invention provides an isolated mammalian IPAS polypeptide encoded by the nucleic acid molecule as defined above. In a preferred form, the said polypeptide has an amino acid sequence according to SEQ ID NO: 3 of the Sequence Listing. However, the polypeptide according to the invention is not to be limited strictly to a polypeptide with an amino acid sequence identical with SEQ ID NO: 3 in the Sequence Listing. Rather the invention encompasses polypeptides carrying modifications like substitutions, small deletions, insertions or inversions, which polypeptides nevertheless have substantially the biological activities of the IPAS polypeptide. Included in the invention are consequently polypeptides, the amino acid sequence of which is at least 90% homologous, preferably at least 95% homologous, with the amino acid sequence shown as SEQ ID NO: 3 in the Sequence Listing.

In yet another aspect, the invention provides a vector comprising the nucleic acid sequence as defined above. The term "vector" refers to any carrier of exogenous DNA that is useful for transferring the DNA to a host cell for replication and/or appropriate expression of the exogenous DNA by the host cell. The said vector can be a replicable expression vector, which carries and is capable of mediating the expression of a nucleic acid sequence according to the invention. In the present context, the term "replicable" means that the vector is able to replicate in a given type of host cell into which it has been introduced. Examples of vectors are viruses such as bacteriophages, cosmids, plasmids and other

recombination vectors. Nucleic acid molecules are inserted into vector genomes by methods well known in the art.

Included in the invention is also a cultured host cell harboring a vector according to the invention. Such a host cell can be a prokaryotic cell, a unicellular eukaryotic cell or a cell derived from a multicellular organism. The host cell can thus e.g. be a bacterial cell such as an *E. coli* cell; a cell from a yeast such as *Saccharomyces cerevisiae* or *Pichia pastoris*, or a mammalian cell. The methods employed to effect introduction of the vector into the host cell are standard methods well known to a person familiar with recombinant DNA methods. The invention also includes a process for production of a mammalian IPAS polypeptide, comprising culturing the said host cell under conditions whereby said polypeptide is produced, and recovering said polypeptide.

In a further important aspect, the invention provides a (screening) method for identifying an agent useful for activating the expression of a mammalian IPAS nucleic acid molecule, said method comprising the steps

- (i) contacting a candidate agent with a mammalian IPAS nucleotide acid molecule, or with a mammalian IPAS polypeptide, according to the invention; and
- (ii) determining whether said candidate agent activates the expression of the said mammalian IPAS nucleic acid molecule, or stimulates the biological activities of the said polypeptide.

For screening purposes, appropriate host cells can be transformed with a vector having a reporter gene under the control of the IPAS gene according to this invention. The expression of the reporter gene can be measured in the presence or absence of an agent with known activity (i.e. a standard agent) or putative activity (i.e. a "test agent" or "candidate agent"). A change in the level of expression of the reporter gene in the presence of the test agent is compared with that effected by the standard agent. In this way, active agents are identified and their relative potency in this assay determined.

As used herein, the term "reporter gene" means a gene encoding a gene product that can be identified using simple, inexpensive methods or reagents and that can be operably linked to an IPAS sequence. Reporter genes such as, for example, a luciferase, β -galactosidase, alkaline phosphatase, or green fluorescent protein reporter gene, can be used to determine transcriptional activity in screening assays according to the invention (see, for example, 5 Goeddel (ed.), *Methods Enzymol.*, Vol. 185, San Diego: Academic Press, Inc. (1990); see also Sambrook, *supra*).

As used herein, the term "agent" means a biological or chemical compound such as a 10 simple or complex organic molecule, a peptide, a protein or an oligonucleotide. Such an agent, identified in the methods according to the invention, is potentially useful e.g. in the identification, development and manufacture of medicaments for the inhibition of angiogenesis and/or tumor growth, including angiogenic diseases related to ischemic cardiovascular lesions, stroke, or diabetic microvascular diseases.

15 Consequently, the invention also provides a method for the treatment of angiogenic disease or tumor growth, comprising administering to a subject an effective amount of an agent identified by the method described above. The term "treatment" means any treatment of a diseases in a mammal, including: (i) preventing the disease, i.e. causing the clinical 20 symptoms of the disease not to develop; (ii) inhibiting the disease, i.e. arresting the development of clinical symptoms; and/or (iii) relieving the disease, i.e. causing the regression of clinical symptoms. The term "effective amount" means a dosage sufficient to provide treatment for the disease state being treated. This will vary depending on the patient, the disease and the treatment being effected.

25 EXPERIMENTAL METHODS

Throughout this description the terms "standard protocols" and "standard procedures", 30 when used in the context of molecular biology techniques, are to be understood as protocols and procedures found in an ordinary laboratory manual such as: Current Protocols in

Molecular Biology, editors F. Ausubel et al., John Wiley and Sons, Inc. 1994, or Sambrook, J., Fritsch, E.F. and Maniatis, T., Molecular Cloning: A laboratory manual, 2nd Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY 1989.

5 *Plasmid Construction*

pcDNA3 IPAS was made by insertion of the *EcoRI*-*NotI* fragment from pT7T3D IPAS (GenBank Acc: AA028416) into *EcoRI*-*NotI* digested pcDNA3 plasmid (Invitrogen).

PCMV IPAS or pFLAG IPAS contained *HindIII*-*XbaI* or *BamHI*-*XbaI* fragment from
10 pcDNA3 IPAS in corresponding site of pCMV4 or pCMV FLAG plasmid, respectively ⁶.
HRE-luciferase, XRE-luciferase, and pCMV HIF-1 α are described elsewhere ^{12 20}.

pBluescript mHLF was gift from Dr. Y. Fujii-Kuriyama and used for construction of
pCMV mHLF. For the construction of the pGST, a plasmid for *in vitro* translation of GST-
fusion protein, GST cDNA and multiple cloning site of pGEX-4T-3 (Amersham Pharmacia
15 Biotech) was amplified by PCR with *BglII* and *HindIII* linker, and subcloned into *BglII*-
HindIII site of pSP72 vector (Promega). pGST IPAS was made by insertion of PCR-cloned
IPAS cDNA with *BamHI* and *XhoI* linker into *BamHI*-*XhoI*-digested pGST. GAL4 HIF-
1 α /1-826, 1-330, 1-652, 526-826 were as previously described ⁶. For pCMX GAL4-IPAS
or pCMX VP-16 IPAS construction, *EcoRI*-*XbaI* or *BamHI*-*XbaI* fragment of pcDNA3
20 IPAS was inserted into *EcoRI*-*NheI* site of pCMX GAL4 or to *BamHI*-*NheI* site of pCMX
VP16, respectively. PCMXVP16-Arnt was gift from Dr. I. Pongratz. To make antisense
IPAS expression plasmid, full length IPAS cDNA with *EcoRI*-*BamHI* linker was inserted
in inverted direction to *BamHI*-*EcoRI* site of pcDNA3 plasmid.

25 *Cell Culture and Transfection*

Hepalclc7, HeLa, and COS7 cells were from ATCC. Hepa IPAS cells were established by
stable transfection of Hepalclc7 cells with pEFIRESpuro IPAS and puromycin (5 μ g/ml)
selection. Transient transfections were carried out by the lipofection procedure in 28 cm²
30 culture plates. In luciferase assay, 0.5 μ g of reporter plasmids and indicated amounts

expression plasmids were transfected. Hypoxic- or TCDD treatment of the cells was previously described¹².

Northern Blot and In Situ Hybridization Analysis

5

Poly(A)⁺ RNAs (4.5 µg) from various tissues of 8 week-old C57Bl6 mice or Hepa1c1c7 and Hepa IPAS cells were obtained by guanidiumthiocyanate methods followed by oligo dT-beads purification (Dynal) and analyzed by Northern blot using ³²P-labeled cDNA probes of mIPAS (nt 623-897), mPGK1 (nt 426-771), mVEGF3 (nt 24-466), mCYP1A1 (nt 874-1199), and β-actin (nt 930-1075). Total RNA (20 µg) from mouse corneal epithelium primary culture or Hepa1c1c7 cells was separated and probed with radiolabeled mVEGF3 cDNA (nt 24-466) probe. *In situ* hybridization of tissue sections from 8 week-old C57Bl6 mice using ³⁵S-labeled mIPAS or mHIF-1α antisense RNA probe was performed as previously described²¹.

15

Electrophoretic Mobility Shift Assay

Nuclear extracts from either normoxic or hypoxic cells were prepared as described before¹². Ten microgram of the nuclear extract was incubated with ³²P-labeled HRE oligonucleotide in a buffer containing 0.1 µg of sonicated, denatured calf thymus DNA in 10 mM Tris-HCl (pH 7.5), 60 mM KCl, 50 mM NaCl, 1 mM MgCl₂, 1 mM EDTA, 5 mM dithiothreitol (DTT), 5% glycerol. Various combination of *in vitro* translated proteins (5 µl each) were mixed with HRE probe in a solution containing 10 mM Hepes, 100 mM KCl, 0.1 mM EDTA, 3 mM MgCl₂, 4 mM spermidine, 0.5 mM DTT, 10 % glycerol, 20 ng/µl tRNA, 1 ng/µl salmon-sperm DNA. The protein-DNA complexes were separated on 4% polyacrylamid gel in 0.5X TBE buffer (1xTBE; 89 mM Tris, 89 mM Boric acid, 5 mM EDTA).

25

In Vitro Protein Interaction Assay

GST-fused IPAS or GAL4-fusion of various fragments of HIF-1 α were generated by translation either in the presence or absence of ³⁵S-labeled methionine in rabbit reticulocyte lysate (Promega). Protein concentration of GST-IPAS or GAL4- HIF-1 α s was determined on the basis of incorporated ³⁵S-labeled methionine. Equal amount of ³⁵S-labeled, *in vitro* translated Arnt, HIF-1 α or IPAS were incubated with GST IPAS or GAL4- HIF-1 α s for 1 h at room temperature, followed by incubation with anti-GST antibody (Amersham Pharmacia Biotech) or anti-GAL4 antibody (Upstate Biotechnology) conjugated Protein A Sepharose (Amersham Pharmacia biotech) for another 1 h at room temperature. After brief centrifugation, coimmunoprecipitated proteins were analyzed by SDS-PAGE.

Isolation of Murine Corneal Epithelial Cells

Six-week-old C57Bl6/J healthy mice were killed with a lethal dose of CO₂. The eyes were enucleated and the corneal tissue was dissected in DME medium supplemented with 10% bovine calf serum under a stereomicroscope. The corneal tissue was cut into small pieces under sterile conditions and washed with DMEM twice. The tissue masses were placed onto a gelatin-coated tissue culture plate and incubated in DMEM with 10% bovine calf serum supplemented with human recombinant FGF- β at the concentration of 3 ng/ml. After incubation in 5% CO₂ for 8 days, corneal epithelial cells grown to nearly confluence were trypsinized. A single cell suspension was then seeded onto 21.5 cm² culture dishes and cells were grown under the same condition as described above.

EXAMPLES

EXAMPLE 1: Identification of IPAS sequence

Hidden Markov Model profiles³ were designed using the HMMER 1,8,3 software¹⁹ from nucleotide sequences corresponding to the PAS domain of a selected number of

bHLH/PAS factors. A mouse EST database at GenBank (<http://www.ncbi.nlm.nih.gov>) was screened and an EST clone of 460 bp (GenBank Acc: AA028416; SEQ ID NO: 1) containing a bHLH (basic-helix-loop-helix) PAS motif, was identified.

5 DNA sequence analysis revealed that IPAS cDNA (SEQ ID NO: 2) contains an open reading frame of 921 nucleotides, encoding a polypeptide of 307 amino acids (Fig. 1a; SEQ ID NO: 3). The predicted polypeptide was designated IPAS (Inhibitory PAS Domain Protein)

10 Alignment analysis of this amino acid sequence with known bHLH PAS factors showed high similarity to HIF-1 α ⁴ and HLF⁵ in the N-terminal bHLH domain (75 % and 76 % identity, respectively; Fig 1b), and to a lesser extent within PAS region (34% and 36 % in the PAS A, and 40 % and 36 % in the PAS B domain, respectively; Fig. 1b). Notably, IPAS lacks the sequence corresponding to C-terminal region of HIF-1 α and HLF, in which
15 two transactivation domains (NTAD and CTAD) have been identified.

EXAMPLE 2: IPAS mRNA is expressed predominantly in the eye

20 Northern blot analysis of poly(A)⁺ RNA from a variety of mouse tissues demonstrated that IPAS mRNA was expressed predominantly in the eye and at lower levels in the cerebellum and the cerebrum. No obvious expression in was detected in other tested mouse tissues, indicating a very tissue-restricted expression pattern of IPAS mRNA (Fig. 1c).

25

EXAMPLE 3: IPAS expression is observed in the epithelial cell layer of the cornea

To characterize the spatial expression pattern of the IPAS gene in the eye and cerebellum, *in situ* hybridization was performed. Intense IPAS expression was observed in the
30 epithelial cell layer of the cornea (Fig. 1d and 1e) and with lower intensity in the layers of ganglion cells, inner nuclear cells, and rods and cones of the retina (Fig. 1h and 1i).

Expression of HIF-1 α mRNA was detected by *in situ* hybridization at low levels in the epithelium of the cornea (Fig. 1f and 1g), demonstrating remarkably dominant expression of IPAS over HIF-1 α in these cells. HIF-1 α was also expressed in the same layers of retina where IPAS expression was observed (Fig. 1j and 1k). In the cerebellum, expression of IPAS was limited to the Purkinje cell layer (Fig. 1l and 1m), whereas HIF-1 α did not show any localized expression throughout the sections (Fig. 1j and 1k). Both IPAS and HIF-1 α mRNAs were observed as weak diffuse signal over nonspecific background levels in certain areas of the cerebrum (data not shown).

EXAMPLE 4: Coexpression of IPAS reduces hypoxia-inducible reporter gene expression in HeLa cells

The structural similarity of IPAS to hypoxia-inducible transcription factors and the colocalization of IPAS and HIF-1 α in mouse cornea prompted us to investigate the role of IPAS in transcriptional control of cellular responsiveness to hypoxia. We performed in HeLa cells a transient transfection assay using a hypoxia-response element- (HRE-) driven luciferase reporter in the absence or presence of transiently expressed IPAS. Incubation of the cells under hypoxic (1% O₂) conditions induced 4.2-fold activation of the reporter gene, representing the induced transactivation function of endogenous hypoxia-inducible factors (Fig. 2a). Coexpression of IPAS reduced hypoxia-inducible reporter gene in HeLa cells stimulated to a high level of luciferase expression in hypoxia-dependent manner (Fig. 2b and Fig. 2c, respectively), indicating that IPAS acts as a dominant negative regulator of the function of endogenous hypoxia-inducible factors. IPAS had no effect on hypoxia-induced protein stabilization of HIF-1 α and HLF (Fig. 2d), which has previously been shown to represent a critical initial step in the activation of HIF-1 α or HLF function^{6 7 8}. Thus, IPAS seems to inhibit more down-stream steps in signal transduction mediated by hypoxia-inducible transcription factors.

EXAMPLE 5: IPAS mediates down-regulation of hypoxia-inducible gene expression –
IPAS impairs interaction between HIF-1 α and the HRE

To further investigate the role of IPAS in regulation of HIF-mediated signaling pathways in
5 hypoxic cells, we generated cells stably overexpressing IPAS by stable transfection of
mouse hepatoma Hepa1c1c7 cells. Expression of IPAS mRNA in the stably transfected
cells was confirmed by Northern blot analysis, whereas the parental Hepa1c1c7 cells did
not show any detectable endogenous IPAS expression (Fig. 3a). Wild type Hepa1c1c7 cells
cultured under hypoxic conditions showed markedly increased expression of mRNAs
10 encoding phosphoglycerate kinase1 (PGK1) and vascular endothelial growth factor
(VEGF) (Fig. 3a), both of which have been demonstrated to be induced under hypoxic
conditions in a variety of cell lines ^{9 10}. In response to hypoxia, Hepa IPAS cells showed
decreased levels of induction of these genes (45% and 48% reduction in PGK1 and VEGF
activation, respectively; Fig. 3a). IPAS-mediated down-regulation of hypoxia-inducible
15 gene expression seemed to be at the transcriptional level, since activation of a transiently
transfected HRE-driven reporter gene by hypoxia was significantly lower in Hepa IPAS
cells than in wild type cells (Fig. 3b). Reporter gene activation was even suppressed in
Hepa IPAS cells following transient overexpression of HIF-1 α , indicating that IPAS
impairs productive interaction between HIF-1 α and the HRE.

EXAMPLE 6: IPAS impairs DNA binding activity of the HIF-1 α /Arnt complex

Mobility shift assay was carried out as described by Gradin et al.¹². In strong support of the
25 results obtained in Example 5, HRE-specific DNA binding activity by the HIF-1 α /Arnt
heterodimeric complex was lower in nuclear extract from either normoxic or hypoxic Hepa
IPAS cells than corresponding nuclear extracts from wild-type cells (Fig. 3c).

EXAMPLE 7: Negative regulation by IPAS is specific to HIF-mediated signaling pathways.

It was examined whether negative regulation by IPAS is specific to HIF-mediated signaling pathways. The aryl hydrocarbon receptor (AhR), which mediates gene regulation in response to xenobiotic chemicals, is also a member of the bHLH/PAS transcription factor family and shares the dimerization partner factor Arnt with HIF-1 α ¹¹. Incubation of the wild-type Hepa 1c1c7 with 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) massively induced mRNA expression of the AhR target gene cytochrome P-4501A1(CYP1A1). In contrast to hypoxia-inducible gene expression, TCDD-induced expression of CYP1A1 mRNA was unperturbed in Hepa IPAS cells which showed an induction response similar to that observed in wild type cells (Fig. 3d). Consistent with these data, very similar levels of activation of a xenobiotic response element (XRE)-driven reporter gene by the ligand-stimulated AhR/Arnt heterodimeric complex¹² was observed both in the wild type and the IPAS overexpressing Hepa cells (Fig. 3e). Taken together, IPAS seems to preferentially target HIF-1 α to act as a dominant negative regulator of hypoxia-inducible gene expression.

EXAMPLE 8: The inhibitory action of IPAS is mediated by direct interaction with HIF-1 α

It was tested whether the inhibitory action of IPAS is mediated by direct interaction with HIF-1 α or Arnt. Radiolabeled, *in vitro* translated HIF-1 α or Arnt were incubated with glutathione S-transferase- (GST-) IPAS fusion proteins and analyzed by immunoprecipitation assays using anti-GST antibodies (Amersham Pharmacia Biotech). GST-IPAS was coprecipitated with HIF-1 α but not with Arnt, demonstrating specific physical interaction between IPAS and HIF-1 α (Fig. 4a).

EXAMPLE 9: The N-terminal part of HIF-1 α is responsible for the physical interaction with IPAS

To identify the domain of HIF-1 α essential for interaction with IPAS, we incubated various fragments of HIF-1 α (see Kallio et al.; ref. 18) fused to the GAL4 minimal DNA binding domain and radiolabeled IPAS generated by *in vitro* translation, and immunoprecipitated this material by anti GAL-4 antibodies (Upstate Biotechnology). GAL4-HIF-1 α /1-826 (full length), /1-330, and /1-652 clearly coprecipitated IPAS whereas GAL4-HIF-1 α /526-826 and GAL4 DBD did not. Together, N-terminal structure of HIF-1 α mainly composed of bHLH/PAS motif is responsible for the physical association with IPAS (Fig. 4b). In support of these observations, mammalian two-hybrid assay employing GAL4- HIF-1 α /1-330 and VP16-IPAS demonstrated interaction between IPAS and N-terminal part of HIF-1 α in the cells (Fig. 4c). On the other hand, in analogy to the results from pull down assay, GAL-4-IPAS and VP16-Arnt failed to show any interaction (Fig. 4d).

EXAMPLE 10: IPAS inhibits DNA binding activity of HIF-1 α /Arnt complex

To elucidate the function of IPAS/HIF-1 α complex, Electrophoretic Mobility Shift Assay using HRE oligonucleotide probe and *in vitro* translated proteins was performed. IPAS/HIF-1 α heterodimer, as well as HIF-1 α or IPAS by itself, was abortive in binding to HRE. Thus IPAS/HIF-1 α complex seemed to be inactive in mediating expression of the genes under control of HRE. Moreover, DNA binding activity of HIF-1 α /Arnt complex was inhibited by the copresence of IPAS but not by the control translation product (Fig. 4e), indicating that the IPAS/HIF-1 α complex might functionally dominate over HIF-1 α /Arnt DNA binding complex.

EXAMPLE 11: Introduction of IPAS antisense into cornea cells stimulates expression and hypoxia inducibility of the VEGF gene

What is the significance of dominant negative function of IPAS in hypoxia signaling and its massive expression in, for example, cornea epithelium? A hallmark of normal cornea is a total avascularity and maintenance of transparency is essential to corneal function. By an overnight eye closure, corneal environment can be enough hypoxic to stimulate hypoxia-inducible gene expression^{13 14}, however, neovascularization in cornea is usually prevented although underlying mechanisms are unknown.

Given the fact IPAS down regulates hypoxia-responsive VEGF expression, we tried to elucidate the effect of IPAS on hypoxia-inducible VEGF expression in cornea. For this purpose, a primary culture of the cornea epithelium cells was transfected with antisense IPAS expression plasmid (or control empty vector) to manipulate IPAS level and incubated with or without hypoxic stimulation for 24 h, thereafter VEGF mRNA expression was monitored in comparison with hepatoma cell lines by Northern Blotting. Hepatoma cell lines showed high level induction of VEGF by hypoxic treatment as previously shown^{10 12} (Fig. 5). In sharp contrast, cornea cells transfected with control vector demonstrated low basal level and modest induction of VEGF expression by hypoxia, which might represent the mechanism for a low profile of corneal angiogenesis. Strikingly, introduction of IPAS antisense into the cornea cells recovered both basal expression and hypoxia inducibility of VEGF gene (Fig. 5), indicating that IPAS may have an important role in silencing angiogenic VEGF expression in cornea especially in hypoxic conditions.

REFERENCES

1. Bunn, H. F. & Poyton, R. O. Oxygen sensing and molecular adaptation to hypoxia. *Physiol Rev* 76, 839-885 (1996).
2. Wenger, R. H. Mammalian oxygen sensing, signalling and gene regulation. *J. Exp. Biol.* 203, 1253-1263 (2000).

3. Krogh, A., Brown, M., Mian, I. S., Sjolander, K. & Haussler, D. Hidden Markov models in computational biology. Applications to protein modeling. *J. Mol. Biol.* 235, 1501-1531 (1994).
4. Wang, G. L., Jiang, B. H., Rue, E. A. & Semenza, G. L. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O₂ tension. *Proc Natl Acad Sci U S A* 92, 5510-5514 (1995).
5. Ema, M. *et al.* A novel bHLH-PAS factor with close sequence similarity to hypoxia-inducible factor 1 α regulates the VEGF expression and is potentially involved in lung and vascular development. *Proc Natl Acad Sci U S A* 94, 4273-4278 (1997).
6. Kallio, P. J., Wilson, W. J., O'Brien, S., Makino, Y. & Poellinger, L. Regulation of the hypoxia-inducible transcription factor 1 α by the ubiquitin-proteasome pathway. *J Biol Chem* 274, 6519-6525 (1999). See also International Patent Application WO 00/29437.
7. Maxwell, P. H. *et al.* The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis [see comments]. *Nature* 399, 271-275 (1999).
8. Wiesener, M. S. *et al.* Induction of endothelial PAS domain protein-1 by hypoxia: characterization and comparison with hypoxia-inducible factor-1 α . *Blood* 92, 2260-2268 (1998).
9. Li, H., Ko, H. P. & Whitlock, J. P. Induction of phosphoglycerate kinase 1 gene expression by hypoxia. Roles of Arnt and HIF1 α . *J Biol Chem* 271, 21262-21267 (1996).
10. Forsythe, J. A. *et al.* Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. *Mol. Cell Biol.* 16, 4604-4613 (1996).
11. Poellinger, L. in *Inducible gene expression* (ed. Baeuerle, P. A.) 177-205 (Birkhäuser, Boston, 1995).
12. Gradin, K. *et al.* Functional interference between hypoxia and dioxin signal transduction pathways: competition for recruitment of the Arnt transcription factor. *Mol Cell Biol* 16, 5221-5231 (1996).

13. Thakur, A., Willcox, M. D. & Stapleton, F. The proinflammatory cytokines and arachidonic acid metabolites in human overnight tears: homeostatic mechanisms. *J. Clin. Immunol.* 18, 61-70 (1998).
14. Sack, R. A., Beaton, A. R. & Sathe, S. Diurnal variations in angiostatin in human
5 tear fluid: a possible role in prevention of corneal neovascularization. *Curr. Eye. Res* 18, 186-193 (1999).
15. Ravi, R. *et al.* Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1 α . *Genes Dev.* 14, 34-44 (2000).
16. Zundel, W. *et al.* Loss of PTEN facilitates HIF-1-mediated gene expression. *Genes*
10 *Dev.* 14, 391-396 (2000).
17. Li, J. *et al.* PR 39, a peptide regulator of angiogenesis. *Nat. Med.* 6, 49-55 (2000).
18. Norton, J. D., Deed, R. W., Craggs, G. & Sablitzky, F. Id helix-loop-helix protein in cell growth and differentiation. *Trends Cell Biol.* 8, 58-65 (1998).
19. Eddy, S. R. Multiple alignment using hidden Markov models. *Ismb* 3, 114-120
15 (1995).
20. Kallio, P. J. *et al.* Signal transduction in hypoxic cells: inducible nuclear translocation and recruitment of the CBP/p300 coactivator by the hypoxia-inducible factor-1 α . *Embo J* 17, 6573-6586 (1998).
21. Bertilsson, G. *et al.* Identification of a human nuclear receptor defines a new
20 signaling pathway for CYP3A induction. *Proc. Natl. Acad. Sci. USA* 95, 12208-12213 (1998).

CLAIMS

1. An isolated nucleic acid molecule selected from:
 - 5 (a) nucleic acid molecules comprising a nucleotide sequence set forth as SEQ ID NO: 2;
 - (b) nucleic acid molecules comprising a nucleotide sequence capable of hybridizing, under stringent hybridization conditions, to a nucleotide sequence complementary the polypeptide coding region of a nucleic acid molecule as defined in (a) and which
 - 10 codes for a biologically active mammalian IPAS polypeptide or a functionally equivalent modified form thereof; and
 - (c) nucleic acid molecules comprising a nucleic acid sequence which is degenerate as a result of the genetic code to a nucleotide sequence as defined in (a) or (b) and which codes for a biologically active mammalian IPAS polypeptide or a functionally
 - 15 equivalent modified form thereof.
2. An isolated mammalian IPAS polypeptide encoded by the nucleic acid molecule according to claim 1.
- 20 3. The isolated mammalian IPAS polypeptide according to claim 2 having an amino acid sequence set forth as SEQ ID NO: 3 in the Sequence Listing
4. A vector comprising the nucleic acid sequence as defined in claim 1.
- 25 5. A replicable expression vector, which carries and is capable of mediating the expression of a nucleic acid sequence as defined in claim 1.
6. A cultured host cell harboring a vector according to claim 4 or 5.

7. A process for production of a mammalian IPAS polypeptide, comprising culturing a host cell according to claim 6 under conditions whereby said polypeptide is produced, and recovering said polypeptide.
- 5 8. A method for identifying an agent useful for activating the expression of a mammalian IPAS nucleic acid molecule, said method comprising the steps
(i) contacting a candidate agent with a mammalian IPAS nucleotide acid molecule according to claim 1; and
(ii) determining whether said candidate agent activates the expression of the said
10 mammalian IPAS nucleic acid molecule.
9. A method for identifying an agent useful for the inhibition of angiogenesis and/or tumor growth, said method comprising the steps
(i) contacting a candidate agent with a mammalian IPAS nucleotide acid molecule
15 according to claim 1; and
(ii) determining whether said candidate agent activates the expression of the mammalian IPAS nucleotide sequence, such activation being indicative for an agent useful for the inhibition of angiogenesis and/or tumor growth.
- 20 10. A method for identifying an agent useful for stimulating the biological activities of a mammalian IPAS polypeptide, said method comprising the steps
(i) contacting a candidate agent with the mammalian IPAS polypeptide according to claim 2 or 3; and
(ii) determining whether said candidate agent stimulates the biological activities of
25 the said polypeptide.
11. A method for identifying an agent useful for the inhibition of angiogenesis and/or tumor growth, said method comprising the steps
(i) contacting a candidate agent with a mammalian IPAS polypeptide according to
30 claim 2 or 3; and

- 24 -

(ii) determining whether said candidate agent stimulates the biological activities of the said polypeptide, such stimulation being indicative for an agent useful for the treatment of a medical condition related to angiogenesis and/or tumor growth.

- 5 12. Use of an agent identified by the method according to any one of claims 8 to 11 in the manufacture of a medicament for the treatment of angiogenic disease or tumor growth.
- 10 13. A method for the treatment of angiogenic disease or tumor growth, comprising administering to a subject an effective amount of an agent identified by the method according to any one of claims 8 to 11.
14. The use or method according to claim 12 or 13, wherein said angiogenic disease is related to ischemic cardiovascular lesions, stroke, or diabetic microvascular diseases.

15

1/11




Fig. 1

3/11





Fig. 2




Fig. 2 (continued)

SUBSTITUTE SHEET (RULE 26)

5/11




Fig. 3

6/11




Fig. 3 (continued)

SUBSTITUTE SHEET (RULE 26)

7/11




Fig. 3 (continued)




Fig. 4

9/11




Fig. 4 (continued)

10/11




Fig. 4 (continued)




Fig. 5

- 1 -

SEQUENCE LISTING

<110> Pharmacia AB

<120> Screening methods

<130> 00244

<140>

<141>

<160> 3

<170> PatentIn Ver. 2.1

<210> 1

<211> 460

<212> DNA

<213> Mus musculus

<300>

<308> GenBank / AA028416

<309> 1996-09-16

<400> 1

```

gccatggcgt tggggctgca ggcgctgagg tcgaacaccg agctgcggaa ggagaagtcg 60
cgggaccgcc cgcagccggc gcacgaggag acggaggtgc tgtaccagct ggcgcacact 120
ctgccctttg cgcgcggcgt cacacctnnc tggacaaggc ctccatcatg cgcctcacia 180
tcagctacct gcgcatgacc gcctctgcgc acagantgga aaaaggggga gagccactgg 240
acgcctgcta cctgaaggcc ctggagggtt tcgtcatggt actcaccgcc gagggagaca 300
tggettacct gtcggaaaat gtcagcaagc acctgggcct cagtcagtgg acctctgttc 360
ctctccctg atacataacc ccactcctgg taccaatttc tctctggagc tcattggaca 420
cagtatcttt gatatttatca tccctgtgac caagaggaac 460

```

<210> 2

<211> 1100

<212> DNA

<213> Mus musculus

<220>

<221> CDS

<222> (19)..(942)

<400> 2

```

gaattcggca cgagggcc atg gcg ttg ggg ctg cag cgc gtg agg tgc aac 51
Met Ala Leu Gly Leu Gln Arg Val Arg Ser Asn
1 5 10

acc gag ctg cgg aag gag aag tgc cgg gac gcg gcc cgc agc cgg cgc 99
Thr Glu Leu Arg Lys Glu Lys Ser Arg Asp Ala Ala Arg Ser Arg Arg
15 20 25

agc cag gag acg gag gtg ctg tac cag ctg gcg cac act ctg ccc ttt 147
Ser Gln Glu Thr Glu Val Leu Tyr Gln Leu Ala His Thr Leu Pro Phe
30 35 40

gcg cgc gcc gtc agc gcg cac ctg gac aag gcc tcc atc atg cgc ctc 195
Ala Arg Gly Val Ser Ala His Leu Asp Lys Ala Ser Ile Met Arg Leu
45 50 55

```

- 2 -

aca atc agc tac ctg cgc atg cac cgc ctc tgc gca gca ggt gga aaa	243
Thr Ile Ser Tyr Leu Arg Met His Arg Leu Cys Ala Ala Gly Gly Lys	
60 65 70 75	
agg ggg aga gcc act gga cgc ctg cta cct gaa ggc cct gga ggg ttt	291
Arg Gly Arg Ala Thr Gly Arg Leu Leu Pro Glu Gly Pro Gly Gly Phe	
80 85 90	
cgt cat ggt act cac cgc cga ggg aga cat ggc tta cct gtc gga aaa	339
Arg His Gly Thr His Arg Arg Gly Arg His Gly Leu Pro Val Gly Lys	
95 100 105	
tgt cag caa gca cct ggg cct cag tca gtg gac ctc tgt tcc tcc tcc	387
Cys Gln Gln Ala Pro Gly Pro Gln Ser Val Asp Leu Cys Ser Ser Ser	
110 115 120	
ctg ata cat aac ccc act cct ggt acc aat ttc tct ctg gag ctc att	435
Leu Ile His Asn Pro Thr Pro Gly Thr Asn Phe Ser Leu Glu Leu Ile	
125 130 135	
gga cac agt atc ttt gat ttt atc cat ccc tgt gac caa gag gaa ctt	483
Gly His Ser Ile Phe Asp Phe Ile His Pro Cys Asp Gln Glu Glu Leu	
140 145 150 155	
caa gac gcc ctg acc ccc agg ccg aac ctg tca aag aag aag ctg gaa	531
Gln Asp Ala Leu Thr Pro Arg Pro Asn Leu Ser Lys Lys Lys Leu Glu	
160 165 170	
gcc cca aca gag cgc cac ttt tcc ctg cga atg aag agc acg ctc acc	579
Ala Pro Thr Glu Arg His Phe Ser Leu Arg Met Lys Ser Thr Leu Thr	
175 180 185	
agc aga ggg cgc acg ctc aac ctc aaa gcg gcc acc tgg aag gtg ctg	627
Ser Arg Gly Arg Thr Leu Asn Leu Lys Ala Ala Thr Trp Lys Val Leu	
190 195 200	
cac tgc tca gga cat atg agg gcc tac aag ccc cct gca cag act tcc	675
His Cys Ser Gly His Met Arg Ala Tyr Lys Pro Pro Ala Gln Thr Ser	
205 210 215	
cct gcc ggg agc cct cgc tcc gag cct ccc ctg caa tgc ctg gtg ctt	723
Pro Ala Gly Ser Pro Arg Ser Glu Pro Pro Leu Gln Cys Leu Val Leu	
220 225 230 235	
atc tgt gaa gcc atc ccc cag ctc ccc ttc cac gat ggt gct act ctg	771
Ile Cys Glu Ala Ile Pro Gln Leu Pro Phe His Asp Gly Ala Thr Leu	
240 245 250	
ggt ctt cca cag gag aag act ccc atc tct acc tta ttc acc cct ctt	819
Gly Leu Pro Gln Glu Lys Thr Pro Ile Ser Thr Leu Phe Thr Pro Leu	
255 260 265	
tgg aag gca cta ctt tgt ctt gtc aag agg tgg cct gtt cag gtg cta	867
Trp Lys Ala Leu Leu Cys Leu Val Lys Arg Trp Pro Val Gln Val Leu	
270 275 280	
cag ggg aaa ggg act gaa tcc tct ctc ccc tca tgg gtg ttg tgg gcc	915
Gln Gly Lys Gly Thr Glu Ser Ser Leu Pro Ser Trp Val Leu Trp Ala	
285 290 295	
ctt aac cgg aaa aat tgt cct ggc tag gagggagtga aggacatggc	962
Leu Asn Arg Lys Asn Cys Pro Gly	
300 305	

- 3 -

ccagctatcc ttagcccaga aacccacaaa tgtctccaaa accaccataa agacctctcc 1022
 ttgttaggca ccagagaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 1082
 aaaaaaacat gcggccgc 1100

<210> 3
 <211> 307
 <212> PRT
 <213> Mus musculus

<400> 3
 Met Ala Leu Gly Leu Gln Arg Val Arg Ser Asn Thr Glu Leu Arg Lys
 1 5 10 15
 Glu Lys Ser Arg Asp Ala Ala Arg Ser Arg Arg Ser Gln Glu Thr Glu
 20 25 30
 Val Leu Tyr Gln Leu Ala His Thr Leu Pro Phe Ala Arg Gly Val Ser
 35 40 45
 Ala His Leu Asp Lys Ala Ser Ile Met Arg Leu Thr Ile Ser Tyr Leu
 50 55 60
 Arg Met His Arg Leu Cys Ala Ala Gly Gly Lys Arg Gly Arg Ala Thr
 65 70 75 80
 Gly Arg Leu Leu Pro Glu Gly Pro Gly Gly Phe Arg His Gly Thr His
 85 90 95
 Arg Arg Gly Arg His Gly Leu Pro Val Gly Lys Cys Gln Gln Ala Pro
 100 105 110
 Gly Pro Gln Ser Val Asp Leu Cys Ser Ser Ser Leu Ile His Asn Pro
 115 120 125
 Thr Pro Gly Thr Asn Phe Ser Leu Glu Leu Ile Gly His Ser Ile Phe
 130 135 140
 Asp Phe Ile His Pro Cys Asp Gln Glu Glu Leu Gln Asp Ala Leu Thr
 145 150 155 160
 Pro Arg Pro Asn Leu Ser Lys Lys Lys Leu Glu Ala Pro Thr Glu Arg
 165 170 175
 His Phe Ser Leu Arg Met Lys Ser Thr Leu Thr Ser Arg Gly Arg Thr
 180 185 190
 Leu Asn Leu Lys Ala Ala Thr Trp Lys Val Leu His Cys Ser Gly His
 195 200 205
 Met Arg Ala Tyr Lys Pro Pro Ala Gln Thr Ser Pro Ala Gly Ser Pro
 210 215 220
 Arg Ser Glu Pro Pro Leu Gln Cys Leu Val Leu Ile Cys Glu Ala Ile
 225 230 235 240
 Pro Gln Leu Pro Phe His Asp Gly Ala Thr Leu Gly Leu Pro Gln Glu
 245 250 255
 Lys Thr Pro Ile Ser Thr Leu Phe Thr Pro Leu Trp Lys Ala Leu Leu
 260 265 270
 Cys Leu Val Lys Arg Trp Pro Val Gln Val Leu Gln Gly Lys Gly Thr
 275 280 285
 Glu Ser Ser Leu Pro Ser Trp Val Leu Trp Ala Leu Asn Arg Lys Asn
 290 295 300
 Cys Pro Gly
 305

INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 01/01387

A. CLASSIFICATION OF SUBJECT MATTER

IPC7: C07K 14/435, C07K 14/47, A61K 35/12, A61P 35/00
According to international Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC7: C07K, C12N, A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE,DK,FI,NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

WPI DATA, EPO INTERNAL, CHEM.ABS DATA, MEDLINE, EMBASE, BIOSIS

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 0009657 A2 (PRESIDENT AND FELLOWS OF HARVARD COLLEGE), 24 February 2000 (24.02.00), page 2, line 31 - line 35; page 3, line 1 - line 19; page 6, line 17 - line 23 --	1-14
Y	EMBL Databases, accession no. A1322407, publ.date 2000-03-03. 100% identity in 458 nt overlap --	1-14
A	trends in CELL BIOLOGY, Volume 8, February 1998, John D. Norton et al, "Id helix-loop-helix proteins in cell growth and differentiation" page 58 - page 65 --	1-14

☒ Further documents are listed in the continuation of Box C.☒ See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

14 November 2001

Date of mailing of the international search report

15-11-2001

Name and mailing address of the ISA/
Swedish Patent Office
Box 5055, S-102 42 STOCKHOLM
Facsimile No. +46 8 666 02 86

Authorized officer

Ida Christensen/EÖ
Telephone No. +46 8 782 25 00

Form PCT/ISA/210 (second sheet) (July 1998)

INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 01/01387

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>WO 9928469 A1 (GENZYME CORPORATION), 10 June 1999 (10.06.99)</p> <p style="text-align: center;">-- -----</p>	1-14

Form PCT/ISA/210 (continuation of second sheet) (July 1998)

INTERNATIONAL SEARCH REPORT

International application No.
PCT/SE01/01387**Box I** Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: **13-14**
because they relate to subject matter not required to be searched by this Authority, namely:
see next sheet
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/SE01/01387

Claims 13-14 relate to methods of treatment of the human or animal body by surgery or by therapy/ diagnostic methods practised on the human or animal body/Rule 39.1.(iv). Nevertheless, a search has been executed for these claims. The search has been based on the alleged effects of the compounds/compositions.

INTERNATIONAL SEARCH REPORT

Information on patent family members

01/10/01

International application No.

PCT/SE 01/01387

Patent document cited in search report			Publication date	Patent family member(s)		Publication date
WO	0009657	A2	24/02/00	AU	5562999 A	06/03/00
				WO	0010096 A	24/02/00

WO	9928469	A1	10/06/99	AU	1626899 A	16/06/99
				EP	1034267 A	13/09/00
				NO	20002849 A	02/08/00
				US	6274585 B	14/08/01

Form PCT/ISA/210 (patent family annex) (July 1998)